title: The Sweet Pee model for Sglt2 mutation.
abstract: Inhibiting renal glucose transport is a potential pharmacologic approach to treat diabetes. The renal tubular sodium-glucose transporter 2 (SGLT2) reabsorbs approximately 90% of the filtered glucose load. An animal model with sglt2 dysfunction could provide information regarding the potential long-term safety and efficacy of SGLT2 inhibitors, which are currently under clinical investigation. Here, we describe Sweet Pee, a mouse model that carries a nonsense mutation in the Slc5a2 gene, which results in the loss of sglt2 protein function. The phenotype of Sweet Pee mutants was remarkably similar to patients with mutations in the Scl5a2 gene. The Sweet Pee mutants had improved glucose tolerance, higher urinary excretion of calcium and magnesium, and growth retardation. Renal physiologic studies demonstrated a prominent distal osmotic diuresis without enhanced natriuresis. Sweet Pee mutants did not exhibit increased KIM-1 or NGAL, markers of acute tubular injury. After induction of diabetes, Sweet Pee mice had better overall glycemic control than wild-type control mice, but had a higher risk for infection and an increased mortality rate (70% in homozygous mutants versus 10% in controls at 20 weeks). In summary, the Sweet Pee model allows study of the long-term benefits and risks associated with inhibition of SGLT2 for the management of diabetes. Our model suggests that inhibiting SGLT2 may improve glucose control but may confer increased risks for infection, malnutrition, volume contraction, and mortality.
authors.affiliation: The Samuel Lunenfeld Research Institute, TCP Building, Room 5-1015-2, 25 Orde Street, Toronto, Ontario M5T 3H7, Canada.
authors.forename: Joseph P
authors.initials: JP
authors.lastname: Ly
authors.forename: Tuncer
authors.initials: T
authors.lastname: Onay
authors.forename: Karen
authors.initials: K
authors.lastname: Sison
authors.forename: Gavasker
authors.initials: G
authors.lastname: Sivaskandarajah
authors.forename: Venkata
authors.initials: V
authors.lastname: Sabbisetti
authors.forename: Lingli
authors.initials: L
authors.lastname: Li
authors.forename: Joseph V
authors.initials: JV
authors.lastname: Bonventre
authors.forename: Ann
authors.initials: A
authors.lastname: Flenniken
authors.forename: Neal
authors.initials: N
authors.lastname: Paragas
authors.forename: Jon M
authors.initials: JM
authors.lastname: Barasch
authors.forename: S Lee
authors.initials: SL
authors.lastname: Adamson
authors.forename: Lucy
authors.initials: L
authors.lastname: Osborne
authors.forename: Janet
authors.initials: J
authors.lastname: Rossant
authors.forename: Jurgen
authors.initials: J
authors.lastname: Schnermann
authors.forename: Susan E
authors.initials: SE
authors.lastname: Quaggin
mesh_terms: D000042:Absorption / Q000502:physiology; D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D018389:Codon, Nonsense / Q000235:genetics*; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000503:physiopathology; D004195:Disease Models, Animal; D005947:Glucose / Q000378:metabolism; D007687:Kidney Tubules, Proximal / Q000378:metabolism; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D008817:Mice, Mutant Strains; D051297:Sodium-Glucose Transporter 2 / Q000235:genetics* / Q000378:metabolism; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013311:Streptozocin
chemical_list: D018389:Codon, Nonsense; C490299:Slc5a2 protein, mouse; D051297:Sodium-Glucose Transporter 2; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D013311:Streptozocin; D005947:Glucose